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Abstract
Background: The latest generation of shoulder arthroplasty includes canal-sparing respectively stemless designs
that have been developed to allow restoration of the glenohumeral center of rotation independently from the
shaft, and to avoid stem-related complications. The stemless prosthesis design has also recently been introduced
for use in reverse arthroplasty systems.
Methods: We systematically reviewed the literature for studies of currently available canal-sparing respectively
stemless shoulder arthroplasty systems. From the identified series, we recorded the indications, outcome measures,
and humeral-sided complications.
Results: We identified 11 studies of canal-sparing respectively stemless anatomic shoulder arthroplasty implants,
published between 2010 and 2016. These studies included 929 cases, and had a mean follow-up of 26 months
(range, 6 to 72 months). The rates of humeral component-related complications ranged between 0 and 7.9 %. The
studies reported only a few isolated cases of complications of the humeral component. Some arthroplasty systems
are associated with radiological changes, but without any clinical relevance.
Conclusions: All of the published studies of canal-sparing respectively stemless shoulder arthroplasty reported
promising clinical and radiological outcomes in short to midterm follow-up. Long-term studies are needed to
demonstrate the long-term value of these kind of implants.
Keywords: Shoulder arthroplasty, Stemless, Canal-sparing, Total shoulder arthroplasty, Shoulder arthritis,
Posttraumatic shoulder arthritis
Abbreviations: ER, external rotation; IR, internal rotation; CTA, cuff tear arthropathy; MRCT, massive rotator cuff tear;
VAS, Visual Analog Scale; SPADI Index, Shoulder Pain and Disability Index; DASH Score, Disabilities of the Arm,
Shoulder and Hand Score; ASES Score, American Shoulder and Elbow Surgeons Shoulder Score ; WOOS
Index, Western Ontario Osteoarthritis Shoulder Index; e.g., For example; etc., Et cetera
Background
Early development of shoulder arthroplasty can be traced
back to 1950s when Charles Neer, II, described the use of
an implant to treat a proximal humeral fracture [1]. Even-
tually, the indication was widened to include osteoarthritis
treatment. Since Neer’s initial prosthesis, the humeral
stem design has undergone several changes. Results of
total shoulder arthroplasty were first presented in 1974
[2]. The following years saw the introduction of several
variations of stemmed humeral implants, which could be
subdivided into four different generations. Stem design
initially used a monoblock system, then changed to a
modular system, followed by a shift to the use of shorter
stems. Additionally, cemented fixation techniques have
been replaced over time by a press-fit cementless system.
The use of shorter implant stems and the elimination of
humeral cement carry several advantages, including the
preservation of humeral bone stock for potential revisions,
performance of anatomic reconstruction regardless of
posterior offset in anatomic arthroplasty, facilitating
arthroplasty in cases of humeral deformity, prevention of
malpositioning, and avoiding periprosthetic fractures [3].
* Correspondence: hawi.nael@mh-hannover.de
1Department of Shoulder and Elbow Surgery, ATOS Clinic Munich,
Effnerstraße 38, 81925 München, Germany
2Trauma Department, Hannover Medical School, Carl-Neuberg-Str. 1, 30625
Hannover, Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hawi et al. BMC Musculoskeletal Disorders  (2016) 17:376 
DOI 10.1186/s12891-016-1235-0
Commonly reported stem-related complications in-
clude intraoperative humeral fracture, loosening, stress
shielding, and traumatic periprosthetic fracture [4–11].
Fracture sequelae, including severe shaft-head malunion,
can lead to malalignment of the shaft implantation and a
failure to restore the anatomic center of rotation. In re-
vision surgery, stem removal can present a challenge for
the surgeon, potentially requiring an osteotomy or inad-
vertently resulting in an intraoperative fracture [5, 6, 8,
11]. Canal-sparing respectively stemless prostheses were
first available in Europe in 2004. Such implants lack a
conventional diaphyseal humeral stem, are based on
metaphyseal fixation, and do not violate the humeral
canal. In this review article, the terms “canal-sparing” re-
spectively “stemless” refer to implant designs with meta-
physeal fixation using a standard humeral neck cut, and
excluding humeral head resurfacing techniques. Canal-
sparing respectively stemless shoulder arthroplasty must
not be confused with resurfacing techniques that aim to
restore joint congruency by preserving the majority of
the humeral head bone stock and implantation of a me-
tallic cap over the remaining humeral head bone stock
[3, 12–18].
Here we have systematically reviewed the current lit-
erature describing canal-sparing respectively stemless
prostheses in shoulder arthroplasty, particularly with
regards to clinical outcomes and complications related
to the humeral components.
Methods
The senior investigator (FM) and first author (NH) system-
atically scanned an online database system (Pubmed, Goo-
gle Scholar) using the MeSH terms “stemless”, “shoulder
replacement”, “shoulder arthroplasty”, “canal-sparing”, and
“short stem”. Then the resulting list of references was
reviewed to identify potential additional studies. Inclusion
criteria were clinical studies including more than five pa-
tients, using cementless and stemless humeral fixation, and
presenting outcomes and complications.
Statistical analysis was ineffective due to the small num-
ber of cases, as well as the use of different follow-up proto-
cols, study designs, and outcome measures. Therefore, we
performed a descriptive review, with information presented
according to the different investigated prosthetic designs.
For all included series, we recorded and summarized the in-
dications, outcome measures (clinical and radiological), and
complications. The scoring systems of the different studies
are presented systematically. Only complications related to
the humeral component are included.
Results
Our findings are summarized in Tables 1, 2, 3, 4 and 5.
Biomet Total Evolutive Shoulder System
The first available canal-sparing respectively stemless im-
plant was the Biomet Total Evolutive Shoulder System
(TESS, Biomet, Warsaw, IN, USA), which was first used in
Europe in 2004 (Fig. 1). The TESS is a three-component
system, which includes an impaction-implanted 6-armed
corolla that is porous to improve bone ingrowth. We iden-
tified five studies using the TESS, which were published be-
tween 2010 and 2016, and included a total of 155 patients.
Follow-up times ranged from 6 to 45 months. Table 2 pre-
sents the surgical indications. All studies showed clinical
improvement after arthroplasty compared to the preopera-
tive status.
In 2010, Huguet et al. [19] first reported on 63 cases
with a minimum follow-up of three years. Concerning
the TESS stemless humeral implant, the authors report
that in five cases the lateral cortex cracked during
Table 1 Included patients and follow-up
Implant n = included stemless Age (years, mean) FU (months, mean)
2010 Huguet et al. JSES TESS 63 64 45.2
2013 Razmjou et al. JSES TESS 17 69 24
2013 Berth et Pap JOT TESS 41 67 30.8
2015 Maier et al. BMC TESS 12 68 6
2011 Kadum et al. AOTS TESS 22 71 14
2014 Bell et Coghlan Int J Shoulder Surg Mathys Affinis 38 68 12
12 65 24
2011 Schoch et al. Obere Extremitaet Arthrex Eclipse 96 66 13.2
19 62
2012 Brunner et al. Obere Extremitaet Arthrex Eclipse 233 61 23.2
2015 Habermeyer et al. JSES Arthrex Eclipse 78 58 72
2016 Ho et al. JSES Simpliciti 149 66 24
2016 Churchill et al. JBJS Simpliciti 149 66 24
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Table 2 Indication for stemless arthroplasty treatment
Implant N
(stemless)
Primary
osteoarthritis
Posttraumatic
osteoarthritis
Osteo-
necrosis
Rheumatoid
arthritis
CTA MRCT Instability
arthritis
Post
infection
arthtis
Arthritis due to
glenoid
dysplasia
Revision
2010 Huguet et al. JSES TESS 63 60 3
2013 Razmjou et al. JSES TESS 17 17
2013 Berth et Pap JOT TESS 41 41
2015 Maier et al. BMC TESS 12 12
2011 Kadum et al. AOTS TESS 22 19 3
2014 Bell et Coghlan Int J
Shoulder
Surg
Mathys
Affinis
50 50
2011 Schoch et al. Obere
Extremitaet
Arthrex
Eclipse
115 96 19
2012 Brunner et al. Obere
Extremitaet
Arthrex
Eclipse
233 100 70 6 16 3 29 4 5 cases
couldn’t
assigned
2015 Habermeyer et al. JSES Arthrex
Eclipse
78 39 26 3 8 1 1
2016 Ho et al. JSES Simpliciti 149 Not
specified
2016 Churchill et al. JBJS Simpliciti 149 96 % 4 %
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surgery without any sign of instability, and that each of
these cases healed without further intervention. No
other humeral implant-associated complications or
problems were noted.
The remaining four identified studies reported no com-
plications related to the TESS humeral implant. Kadum et
al. [20] analyzed 56 patients, among whom 22 received an
anatomic TESS prosthesis, with a mean follow-up of
14 months. Razmjou et al. [21] compared the anatomic
TESS prosthesis (n = 17) to the Bigliani-Flatow (n = 40)
and the Neer II prosthesis (n = 22), showing no significant
differences in outcome between groups, with a mean
follow-up of 24 months. Berth and Pap [22] compared the
anatomic TESS prosthesis to the Mathys Affinis stemmed
prosthesis, with 41 patients in each group and a mean
follow-up of 30 months. Their results revealed no statisti-
cally significant differences in outcome. Finally, Meier et
al. [23] compared the anatomic TESS prosthesis to the
anatomic stemmed Aequalis Shoulder prosthesis (Tour-
nier, Lyon, France), with 12 cases per group and a 6-
month follow-up. They reported comparable results for
both groups based on the Constant Score.
Table 3 Kind of stemless arthroplasty treatment and approach
Implant n Approach Hemiarthroplasty Total shoulder
arthroplasty
2010 Huguet et al. JSES TESS 63 Deltopectoral 44 19
2013 Razmjou et al. JSES TESS 17 Deltopectoral 17
2013 Berth et Pap JOT TESS 41 Deltopectoral 41
2015 Maier et al. BMC TESS 12 Deltopectoral 12
2011 Kadum et al. AOTS TESS 22 Antero-Superior
(Mackenzie)
Not
assigned
2014 Bell et Coghlan Int J Shoulder
Surg
Mathys
Affinis
50 Deltopectoral 50
2011 Schoch et al. Obere
Extremitaet
Arthrex
Eclipse
115 Deltopectoral 115
2012 Brunner et al. Obere
Extremitaet
Arthrex
Eclipse
233 Deltopectoral 114 119
2015 Habermeyer et
al.
JSES Arthrex
Eclipse
78 Deltopectoral 39 39
2016 Ho et al. JSES Simpliciti 149 Deltopectoral 149
2016 Churchill et al. JBJS Simpliciti 149 Deltopectoral 149
Table 4 Humeral implant related complication
Implant n Percentage of
complication
Kind of stemless humeral implant related complication and
treatment
2010 Huguet et al. JSES TESS 63 7.9 % - Five patients with a small crack of the humeral
lateral cortex intraoperatively, noticed on the first
postoperative radiograph, further conservative treatment
2013 Razmjou et al. JSES TESS 17 0 % -
2013 Berth et Pap JOT TESS 41 0 % -
2015 Maier et al. BMC TESS 12 0 % -
2011 Kadum et al. AOTS TESS 22 0 % -
2014 Bell et
Coghlan
Int J Shoulder
Surg
Mathys
Affinis
50 0 % -
2011 Schoch et al. Obere
Extremitaet
Arthrex
Eclipse
115 0 % -
2012 Brunner et al. Obere
Extremitaet
Arthrex
Eclipse
233 2.3 % - One patient with radiological and asymptomatic loosening
after 24 months
2015 Habermeyer
et al.
JSES Arthrex
Eclipse
78 0 % -
2016 Ho et al. JSES Simpliciti 149 0 % -
2016 Churchill et al. JBJS Simpliciti 149 0 % -
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Table 5 Outcome parameters with radiological humeral conspicuous findings (values are given in mean if not declared different)
2010 Huguet et
al.
JSES TESS 63 Constant
score
Anterior
active
elevation (°)
ER with
elbow to
the side (°)
Radiological humeral component outcome
29.6 75 96 145 20 40 Inconspicuous
2013 Razmjou et
al.
JSES TESS 17 Quick dash WOOS ASES Inconspicuous
54 23 37 85 41 82
Relative
Constant-
Murley
Score
Flexion (°) Abduction
(°)
37 92 69 135 51 121
ER in
neutral (°)
ER 90°
abduction
(°)
IR at 90°
abduction
(°)
18 54 9 61 1 33
Strength
(lbs)
5 10
2013 Berth et Pap JOT TESS 41 DASH score
(points)
Constant
score,
adjusted
(points)
Anteversion
(°)
Inconspicuous
62.1 47.4 40.1 73.2 81.2 115.9
Abduction
(°)
External
rotation (°)
68.2 105 39.1 54.4
2015 Maier et al. BMC TESS 12 Constant
score
Flexion (°) Abduction
(°)
-
33.7 48 94.2 96.9 79.6 85.9
2011 Kadum et al. AOTS TESS
anatomic
22 Quick dash EQ-5D VAS for life
of quality
Inconspicuous
TESS
reverse
17
56 34 0.36 0.73 39 66
2014 Bell et
Coghlan
Int J
Shoulder
Surg
Mathy
Affinis
50 Constant
score
DASH score ASES score Inconspicuous
38 28.84 76.12 49.36 10.79 42.51 88.28
12 24.82 85.75 48.80 5.94 46.39 92.58
SPADI score Active
elevation
(median) (°)
38 64.28 11.05 75 160
12 60.63 5.16 93.18 160
2011 Schoch et al. Obere
Extremitaet
Arthrex
Eclipse
115 Constant
Murley
score
Anteversion
(°)
Abduction
(°)
Inconspicuous
96 44.7 66 118 145 82 105
19 34.6 57 110 140 75 100
External
rotation (°)
96 15 41
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Mathys Affinis Short Stemless Prosthesis
The Mathys Affinis Short Stemless Prosthesis (Mathys,
Betlach, Switzerland) was first available on the European
market in 2009 (Fig. 2). This arthroplasty system has two
components: a humeral metaphyseal implant and a ceramic
humeral head. The metaphyseal implant comprises four
Table 5 Outcome parameters with radiological humeral conspicuous findings (values are given in mean if not declared different)
(Continued)
19 15 38
2012 Brunner et
al.
Obere
Extremitaet
Arthrex
Eclipse
233 Constant
Murley
score (%)
Flexion (°) Abduction
(°)
7.2 % of cases radiolucency between the head and the
screw without clinical consequences
51.6 78.9 105 128 80 120
External
rotation (°)
22 37
2015 Habermeyer
et al.
JSES Arthrex
Eclipse
78 Constant
Murley
score (%)
Flexion (°) Abduction
(°)
Incomplete radiolucent line of the humeral component
smaller than 2 mm in one patient, in three patients
partial osteolyses under the superior part of the
humeral component without loosening, decreased
density of cancellous bone in the greater tuberosity
with the AP view in 34.9 % without influence on
shoulder function.
38.1 75.3 114 141 74 130
External
rotation (°)
25 44
2016 Ho et al. JSES Simpliciti 149 Constant
Murley
score
(adjusted)
Constant
Murley
score
(adjusted)
Constant
Murley
score
(adjusted)
Inconspicuous
<60 y 60–69 y >70 y
51.2 90.5 55.9 105.6 58.2 110.6
ASES score ASES score ASES score
<60 y 60–69 y >70 y
33.2 84.1 39.6 94.3 39.1 93.1
Simple
shoulder
test
Simple
shoulder
test
Simple
shoulder
test
<60 y 60–69 y >70 y
4 10.1 4.3 11 4.6 10.7
External
rotation (°)
External
rotation (°)
External
rotation (°)
<60 y 60–69 y >70 y
35.4 54.9 28.8 55.8 31.3 58.2
Scapular
plane (°)
Scapular
plane (°)
Scapular
plane (°)
<60 y 60–69 y >70 y
107.1 142.4 102.3 149.6 100.9 144.5
2016 Churchill et
al.
JBJS Simpliciti 149 Constant
Murley
Score
(adjusted,
%)
ASES score Simple
shoulder
Test
Inconspicuous
55.6 104.1 38.2 91.9 4.3 10.8
Pain VAS
Score
Scapular
plane (°)
Eternal
rotation (°)
5.9 0.5 102.8 146.6 30.9 56.4
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wings composed of a rough porous titanium structure, with
an osteoconductive calcium phosphate coating to improve
bone ingrowth. This part is inserted with impaction.
In the only published study using this implant, Bell and
Coghlan [24] investigated 50 cases with an indication of
primary osteoarthritis. They reported a 24-month follow-
up for 12 cases, and a 12-month follow-up for 38 cases.
No prosthesis-related intraoperative or postoperative
complications were reported.
Arthrex Eclipse Prosthesis
The Arthrex Eclipse Prosthesis (Arthrex, Naples, USA)
was introduced in 2005 (Fig. 3). This prosthesis com-
prises three components. A fully threaded, cylindrical
central cage unit is inserted over a collar-bearing base-
plate (trunnion) for metaphyseal fixation. The trunnion
covers the resection plane at the anatomical neck, and
joins cortical support. The third component is a co-
rresponding humeral head. In contrast to the other de-
scribed implants, the Arthrex Eclipse is the only
available stemless system that offers screw-in insertion.
Between 2011 and 2015, three studies investigated the
Eclipse prosthesis, including a total of 426 procedures
with a mean follow-up ranging from 13 to 72 months.
Table 2 presents the specific surgical indications. Schoch
et al. [25] analyzed 115 cases, and reported that all of
the radiographs evaluated at the 12-month follow-up
were inconspicuous with regards to loosening or radio-
lucent lines. Brunner et al. [26] published their experi-
ence of using the Eclipse prosthesis in 233 patients after
a mean follow-up of 23 months. They describe one case
in which the implant loosened after 24 months, and they
noted radiolucency between the head and the screw in
7.2 % of cases. However, these radiological changes did
not appear to have any clinical relevance.
In the most recent study of the Eclipse prosthesis,
Habermeyer et al. [27] analyzed 78 patients with a mini-
mum follow-up of 5 years. They reported that one pa-
tient showed an incomplete radiolucent line of the
humeral component of smaller than 2 mm. Additionally,
three patients exhibited partial osteolysis under the su-
perior part of the humeral component, without loosen-
ing of the component. Among the patients, 34.9 %
showed changed cancellous bone density in terms of
stress shielding at the greater tuberosity on the AP view,
without clinical significance. No implant-specific compli-
cations were observed related to the Eclipse prosthesis.
Fig. 1 The Biomet Total Evolutive Shoulder System (TESS; Biomet,
Warsaw, IN, USA) (Figure provided by the manufacturer)
Fig. 2 The Mathys Affinis Short Stemless Prosthesis (Mathys, Betlach,
Switzerland) (Figure provided by the manufacturer)
Fig. 3 The Arthrex Eclipse Prosthesis (Arthrex, Naples, USA) (Figure
provided by the manufacturer)
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Simpliciti Stemless Prosthesis
Clinical use of the Simpliciti Stemless Prosthesis
(Tornier, Bloomington, MN, US) began in France in
2010 (Fig. 4). It is presently the only FDA-approved
stemless respectively canal-sparing implant. It comprises
two pieces—a humeral implant and a head implant—-
which are available in different sizes. Churchill et al. [27]
and Ho et al. [18, 28] both recently published results of
canal-sparing respectively stemless shoulder arthroplasty
with a 24-month follow-up in a total of 298 patients.
Table 2 summarizes the indications. Both studies dem-
onstrated improved outcomes, and no humeral-sided
complications.
Discussion
Six different canal-sparing respectively stemless humeral
implants are presently available on the market, four of
which are described in published studies. The canal-
sparing respectively stemless shoulder prosthesis with
metaphyseal anchoring is a relatively new concept that
reportedly provides good outcomes that are comparable
to stemmed designs in short and midterm evaluations
[19, 21–23, 27]. All of the presently reviewed studies
demonstrated substantial improvement after replace-
ment. Moreover, the studies that compared the canal-
sparing respectively stemless design to stemmed im-
plants showed no differences in outcomes related to the
humeral component [21–23].
The indications for canal-sparing respectively stemless
prosthesis are the same as for stemmed systems. Canal-
sparing respectively stemless implants cannot be used in
cases with poor bone quality, metaphyseal cysts, osteope-
nia, osteoporosis, or other metabolic bone diseases [29],
or in cases with fractures in the metaphyseal area that dis-
turb adequate bony in-growth or primary implant stability.
However, there is not yet any test available to objectively
determine bone quality pre- or intraoperatively [29].
Churchill et al. [18] described the use of a “thumb test” in
which bone quality is intraoperatively assessed by com-
pressing the surface of the neck cut with the thumb. Over-
all, the presently reviewed studies reported only a few
isolated cases of loosening of the stemless component.
Among the various investigated canal-sparing respect-
ively stemless prostheses, the main difference in design
is that the Eclipse is inserted over a screw, while the
TESS, the Simpliciti, and the Affinis prostheses are
inserted using an impaction technique. It appears that
the mechanism of force transmission when the Eclipse
prosthesis is inserted over a screw differs from that dur-
ing impaction implantation of the corolla of the TESS,
the wings of the Affinis, or the Simpliciti prosthesis. This
difference may explain the observed differences in the
surrounding humeral bone, with changed bone mineral
density seen on radiographs, which could be interpreted
as stress shielding beneath the trunnion with the Eclipse
prosthesis. These findings are not correlated with any
negative clinical symptoms, and seem to be purely a
radiographic phenomenon, at least at the midterm
follow-up. Subgroup analysis of these patients reported
by Habermeyer et al. [27] revealed no statistical signifi-
cance in the patient cohort, with a minimum follow-up
of 5 years.
One major advantage of the canal-sparing respectively
stemless prosthesis design is that it can potentially be
used in post-traumatic and deformity cases regardless of
the humeral head–shaft configuration. Restoration of the
glenohumeral center of rotation independently from the
shaft is a key goal in secondary shoulder arthroplasty for
fracture sequelae treatment [30]. Malunion resulting in
metaphyseal–diaphyseal malalignment can make it diffi-
cult or even impossible to implant a stemmed or even a
short-stemmed prosthesis. In such cases, corrective oste-
otomies are associated with poor results [31]. Reports of
these types of special cases are limited to only rare single
cases within the studies. Other advantages of the canal-
sparing respectively stemless prosthesis are that it can
preserve bone stock of the proximal humerus, as well as
avoid humeral stem-related complications in revision
cases requiring stem removal. In a commentary, Athwal
summarized the advantages of the canal-sparing respect-
ively stemless implant as a theoretically decreased surgi-
cal time, less blood loss, bone preservation, and lower
risk of intraoperative and potentially postoperative peri-
prosthetic fractures. Canal-sparing respectively stemless
prostheses are also suitable for posttraumatic joint re-
construction and, when needed, explantation is easier
compared to with the stemmed version. Following ex-
plantation, a stemless prosthesis can be replaced by a
standard-length primary implant [29].
Fig. 4 The Simpliciti Stemless Prosthesis (Tornier, Bloomington, MN,
US) (Figure provided by the manufacturer)
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For the purpose of this review, we chose to include all
available literature evaluating anatomic canal-sparing re-
spectively stemless humeral components in shoulder
arthroplasty. This review article refers to only implant
designs with metaphyseal fixation, and excludes humeral
head resurfacing. It is much easier to achieve glenoid ex-
posure for glenoid component implantation using canal-
sparing respectively stemless implants compared to with
humeral head resurfacing [3, 20].
It must be noted that, all reviewed studies provide only
short or midterm results, and include only a limited
number of patients. Additionally, some studies were re-
ported by the designer or co-developer of the investi-
gated implant, which suggests the possibility of a certain
bias. There are presently ongoing IDE trials, which will
provide more robust and high-quality data on this topic.
Conclusions
All of the published studies describing anatomic canal-
sparing respectively stemless shoulder replacement
showed promising clinical and radiological outcomes over
short to midterm follow-up periods. To date, the available
literature lacks well-designed clinical studies with at least
midterm results.
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